Thomas W. Chalberg, PhD

Thomas W. Chalberg, PhD has a long and successful career in the biotechnology industry. In 2021, they became a Partner at Polymerase Capital and the Founder/CEO of Genascence Corporation. In 2021, they also joined Chameleon Biosciences, Inc. as a Director. From 2016 to 2021, they were the Executive Chairman of iRenix Medical, Inc. and a Director at ethris GmbH. Thomas W. was also the Founder, CEO, and Chief Scientific Officer at SightGlass Vision, Inc. from 2016 to 2021, when the company was acquired by a joint venture between CooperVision and EssilorLuxottica. During that same period, they were also the Chief Operating Officer (Interim) at Oncorus, Inc. From 2006 to 2016, they were the Founder and CEO of Avalanche Biotechnologies, Inc (now Adverum; NASDAQ: ADVM), a leader in gene therapy for eye diseases. Thomas W. also worked at Genentech from 2005 to 2006 as a Marketing and Commercial Operations professional in Ophthalmology and Oncology. Their career began in 1999 when they worked as a Biotechnology Consultant at ZS Associates.

Thomas W. Chalberg, PhD completed their education history with a PhD in Cancer Biology, Genetics, and Ophthalmology from Stanford University School of Medicine in 2005. Prior to that, they obtained an MBA in Entrepreneurship and Biotechnology from the University of California, Berkeley, Haas School of Business in 2011. Thomas W. also earned an A.B. in Biochemical Sciences from Harvard University in 1999. Their education history began with their attendance at Campolindo High School from 1991 to 1995.